At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SPRY ARS PHARMACEUTICALS INC
Trading 06-12 10:52:19 EDT
9.93
+0.34
+3.55%
High10.17Low9.69Vol484.22K
Open9.73D1 Closing9.59Amplitude5.00%
Mkt Cap981.57MTradable Cap548.84MTotal Shares98.85M
T/O4.82MT/O Rate0.88%Tradable Shares55.27M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Drew Brees Collaborates With ARS Pharmaceuticals to Raise Awareness About Living Life With Severe Allergies
THOMSON REUTERS  ·  06-04
Drew Brees Collaborates With ARS Pharmaceuticals to Raise Awareness About Living Life With Severe Allergies
ARS Pharmaceuticals files Form 3 for President Donn Casale, reporting no beneficial ownership
Reuters  ·  06-02
ARS Pharmaceuticals files Form 3 for President Donn Casale, reporting no beneficial ownership
ARS Pharmaceuticals Is Maintained at Overweight by Cantor Fitzgerald
Dow Jones  ·  05-28
ARS Pharmaceuticals Is Maintained at Overweight by Cantor Fitzgerald
ARS Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary
Reuters  ·  05-15
ARS Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary
BUZZ-U.S. STOCKS ON THE MOVE-Cerebras, Papa John's, airline stocks
Reuters  ·  05-15
BUZZ-U.S. STOCKS ON THE MOVE-Cerebras, Papa John's, airline stocks
ARS Pharma Q1 FY26 net loss widens to $60.62 million; revenue more than doubled to $22.68 million
Reuters  ·  05-15
ARS Pharma Q1 FY26 net loss widens to $60.62 million; revenue more than doubled to $22.68 million
ARS Pharmaceuticals Q1 Loss Widens, Revenue Rises; Shares Up Pre-Bell
MT Newswires Live  ·  05-15
ARS Pharmaceuticals Q1 Loss Widens, Revenue Rises; Shares Up Pre-Bell
ARS Pharmaceuticals Q1 revenue beats estimates on neffy sales growth
Reuters  ·  05-15
ARS Pharmaceuticals Q1 revenue beats estimates on neffy sales growth
Earnings Flash (SPRY) ARS Pharmaceuticals Posts Q1 Loss $0.61 a Share, vs. FactSet Est of $0.49 Loss
MT Newswires Live  ·  05-15
Earnings Flash (SPRY) ARS Pharmaceuticals Posts Q1 Loss $0.61 a Share, vs. FactSet Est of $0.49 Loss
ARS Pharmaceuticals Q1 EPS $(0.61) Misses $(0.52) Estimate, Sales $22.681M Beat $22.230M Estimate
Benzinga  ·  05-15
ARS Pharmaceuticals Q1 EPS $(0.61) Misses $(0.52) Estimate, Sales $22.681M Beat $22.230M Estimate
ARS Pharmaceuticals: Anticipate Majority of Medicaid State Plans Adopting Neffy to Their Unrestricted Medicaid Formularies by Early 2027
THOMSON REUTERS  ·  05-15
ARS Pharmaceuticals: Anticipate Majority of Medicaid State Plans Adopting Neffy to Their Unrestricted Medicaid Formularies by Early 2027
ARS Pharmaceuticals Q1 Net Income USD -60.618 Million
THOMSON REUTERS  ·  05-15
ARS Pharmaceuticals Q1 Net Income USD -60.618 Million
ARS Pharmaceuticals Q1 Cash & Investments USD 201 Million
THOMSON REUTERS  ·  05-15
ARS Pharmaceuticals Q1 Cash & Investments USD 201 Million
ARS Pharmaceuticals Inc: CVS Caremark Proposal in Final Stages of Approval Process; Definitive Update Anticipated in Early June
THOMSON REUTERS  ·  05-15
ARS Pharmaceuticals Inc: CVS Caremark Proposal in Final Stages of Approval Process; Definitive Update Anticipated in Early June
ARS Pharmaceuticals Q1 EPS USD -0.61
THOMSON REUTERS  ·  05-15
ARS Pharmaceuticals Q1 EPS USD -0.61
ARS Pharmaceuticals Q1 Revenue USD 22.7 Million VS. Ibes Estimate USD 22.2 Million
THOMSON REUTERS  ·  05-15
ARS Pharmaceuticals Q1 Revenue USD 22.7 Million VS. Ibes Estimate USD 22.2 Million
Press Release: ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update
Dow Jones  ·  05-15
Press Release: ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update
U.S. Earnings Preview: Before Market Open May 15
Dow Jones  ·  05-15
U.S. Earnings Preview: Before Market Open May 15
ARS Pharmaceuticals Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Benzinga  ·  05-15
ARS Pharmaceuticals Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Dow Settles Above 50,000: Investor Sentiment Improves, Fear Index Remains In 'Greed' Zone
Benzinga  ·  05-15
Dow Settles Above 50,000: Investor Sentiment Improves, Fear Index Remains In 'Greed' Zone

Introduction

Company Name.
ARS PHARMACEUTICALS INC
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for patients and parents affected by severe allergic reactions. It is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for patients and their caregivers with type I allergic reactions, including anaphylaxis. The company was founded in 2015 and is based in San Diego, California.
Issue price:
--